

Tracleer - (32 mg; Tablet for suspension, Oral)

| Generic Name | Bosentan | Innovator | Actelion pharmaceuticals |
|-----------------------|--|----------------------|--------------------------|
| Dosage | 32 mg; Tablet for suspension, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Indications for Tracleer: -Pulmonary arterial hypertension (PAH) (WHO Group I) in adults with WHO Class II–IV symptoms to improve exercise ability and decrease clinical worsening | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.